Parallel Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-350
| Closed | – | – | 3661 |
|
|
2024
Q3 | $0 | Hold |
350
| – | – | ﹤0.01% | 3523 |
|
|
2024
Q2 | $0 | Hold |
350
| – | – | ﹤0.01% | 3478 |
|
|
2024
Q1 | $13 | Hold |
350
| – | – | ﹤0.01% | 3271 |
|
|
2023
Q4 | $19 | Hold |
350
| – | – | ﹤0.01% | 3282 |
|
|
2023
Q3 | $31 | Hold |
350
| – | – | ﹤0.01% | 3314 |
|
|
2023
Q2 | $32 | Hold |
350
| – | – | ﹤0.01% | 3324 |
|
|
2023
Q1 | $91 | Hold |
350
| – | – | ﹤0.01% | 3340 |
|
|
2022
Q4 | $74 | Hold |
350
| – | – | ﹤0.01% | 3282 |
|
|
2022
Q3 | $0 | Hold |
350
| – | – | ﹤0.01% | 3666 |
|
|
2022
Q2 | $0 | Hold |
350
| – | – | ﹤0.01% | 3530 |
|
|
2022
Q1 | $0 | Hold |
350
| – | – | ﹤0.01% | 3445 |
|
|
2021
Q4 | $0 | Hold |
350
| – | – | ﹤0.01% | 3455 |
|
|
2021
Q3 | $1K | Hold |
350
| – | – | ﹤0.01% | 3033 |
|
|
2021
Q2 | $1K | Hold |
350
| – | – | ﹤0.01% | 2904 |
|
|
2021
Q1 | $1K | Hold |
350
| – | – | ﹤0.01% | 2761 |
|
|
2020
Q4 | $1K | Hold |
350
| – | – | ﹤0.01% | 2544 |
|
|
2020
Q3 | $1K | Hold |
350
| – | – | ﹤0.01% | 2537 |
|
|
2020
Q2 | $1K | Hold |
350
| – | – | ﹤0.01% | 2415 |
|
|
2020
Q1 | $0 | Buy |
+350
| New | +$386 | ﹤0.01% | 2798 |
|
Parallel Advisors's NAVB Position: Q4 2024 in Review
Parallel Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2024, closing a stake of 350 shares.
Parallel Advisors first reported a position in NAVB in Q1 2020 and held it in 19 quarters. The position peaked at $1K in Q3 2021. 1 fund tracked by Wall St. Rank holds NAVB as of Q4 2024.
- Parallel Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2024 after selling out during the quarter.
- Parallel Advisors sold 350 Navidea Biopharmaceuticals Inc. shares in Q4 2024.
- Parallel Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2020 and held it in 19 quarters.
- Parallel Advisors's Navidea Biopharmaceuticals Inc. position peaked at $1K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2024.
Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.